Vanguard Group Inc. Has $70.12 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Vanguard Group Inc. reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,631,040 shares of the company’s stock after selling 55,910 shares during the period. Vanguard Group Inc. owned 5.66% of Amphastar Pharmaceuticals worth $70,117,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Amphastar Pharmaceuticals by 5.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock worth $217,000 after acquiring an additional 465 shares during the period. Illumine Investment Management LLC boosted its holdings in Amphastar Pharmaceuticals by 2.0% during the third quarter. Illumine Investment Management LLC now owns 27,677 shares of the company’s stock valued at $738,000 after acquiring an additional 551 shares during the period. State of Wyoming boosted its holdings in Amphastar Pharmaceuticals by 21.2% during the third quarter. State of Wyoming now owns 3,301 shares of the company’s stock valued at $88,000 after acquiring an additional 578 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after purchasing an additional 613 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Amphastar Pharmaceuticals by 219.0% in the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after purchasing an additional 703 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Rong Zhou sold 9,787 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total transaction of $256,419.40. Following the sale, the executive vice president directly owned 138,043 shares in the company, valued at approximately $3,616,726.60. The trade was a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Floyd F. Petersen sold 2,426 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.92, for a total value of $62,881.92. Following the completion of the transaction, the director owned 71,368 shares of the company’s stock, valued at $1,849,858.56. The trade was a 3.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,950 shares of company stock valued at $363,925 in the last quarter. Corporate insiders own 27.50% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $19.34 on Friday. The firm’s 50-day moving average is $26.57 and its 200-day moving average is $26.66. The company has a market cap of $877.46 million, a price-to-earnings ratio of 9.53, a PEG ratio of 1.50 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02. Amphastar Pharmaceuticals, Inc. has a 52-week low of $18.93 and a 52-week high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.24). Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. The company had revenue of $183.11 million during the quarter, compared to the consensus estimate of $190.48 million. Equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Zacks Research cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Needham & Company LLC lowered their target price on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Barclays began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Finally, Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $29.50.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.